Compare BC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | LEGN |
|---|---|---|
| Founded | 1845 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | BC | LEGN |
|---|---|---|
| Price | $77.34 | $27.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $83.55 | $61.33 |
| AVG Volume (30 Days) | 656.8K | ★ 2.9M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.81 | $42.68 |
| Revenue Next Year | $5.11 | $30.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $48.83 | $16.24 |
| 52 Week High | $90.25 | $45.30 |
| Indicator | BC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 59.72 |
| Support Level | $74.04 | $25.71 |
| Resistance Level | $84.25 | $29.69 |
| Average True Range (ATR) | 2.95 | 2.10 |
| MACD | -0.34 | 0.01 |
| Stochastic Oscillator | 36.78 | 61.17 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns 442 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.